PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts

FEBS Letters

Volumn 584, Issue 1, 2010, Pages 173-180

  Park, Hyojung ^a   No, A Long Sae Mi ^a   Lee, Jung Min ^a   Chen, Ling ^a   Lee, Soo Young ^b   Lee, Dong Seok ^c   Yim, Mijung ^a  

^a Sookmyung Women's University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

COX 2; CRE; Osteoblast; Osteoclast; Parathyroid hormone; Phosphodiesterase 4; RANKL

Indexed keywords

CRE RECOMBINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PHOSPHODIESTERASE IV INHIBITOR;

ANIMAL CELL; ARTICLE; CALVARIA; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; MALE; MOUSE; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOOXYGENASE 2; HUMANS; MICE; OSTEOBLASTS; OSTEOCLASTS; PARATHYROID HORMONE; RANK LIGAND;

EID: 71549119792     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.11.043     Document Type: Article

References (20)

1. Väänänen H.K., Zhao H., Mulari M., and Halleen J.M. The cell biology of osteoclast function. J. Cell Sci. 113 (2000) 377-381
2. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J.M., Martin T.J., and Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 (1988) 2600-2602
3. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
4. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett III F.S., Frankel W.N., Lee S.Y., and Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 (1997) 25190-25194
5. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., and Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
6. Fu Q., Jilka R.L., Manolagas S.C., and O'Brien C.A. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277 (2002) 48868-48875
7. Park H., Lee Y.S., Lee D.S., and Yim M. Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem. Biophys. Res. Commun. 354 (2007) 178-183
8. Okada Y., Lorenzo J.A., Freeman A.M., Tomita M., Morham S.G., Raisz L.G., and Pilbeam C.C. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J. Clin. Invest. 105 (2000) 823-832
9. Li L., Pettit A.R., Gregory L.S., and Forwood M.R. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev. 17 (2006) 203-216
10. Conti M., and Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76 (2007) 481-511
11. Essayan D.M. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108 (2001) 671-680
12. Takami M., Cho E.S., Lee S.Y., Kamijo R., and Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett. 31 (2005) 832-838
13. Wang D., Christensen K., Chawla K., Xiao G., Krebsbach P.H., and Franceschi R.T. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14 (1999) 893-903
14. Wakabayashi S., Tsutsumimoto T., Kawasaki S., Kinoshita T., Horiuchi H., and Takaoka K. Involvement of phosphodiesterase isozymes in osteoblastic differentiation. J. Bone Miner. Res. 17 (2002) 249-256
15. Datta N.S., and Abou-Samra A.B. PTH and PTHrP signaling in osteoblasts. Cell. Signal. 21 (2009) 1245-1254
16. Kondo H., Guo J., and Bringhurst F.R. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17 (2002) 1667-1679
17. Bisello A., Chorev M., Rosenblatt M., Monticelli L., Mierke D.F., and Ferrari S.L. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J. Biol. Chem. 277 (2002) 38524-38530
18. Spurney R.F., Flannery P.J., Garner S.C., Athirakul K., Liu S., Guilak F., and Quarles L.D. Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J. Clin. Invest. 109 (2002) 1361-1371
19. Wang H., Peng M.S., Chen Y., Geng J., Robinson H., Houslay M.D., Cai J., and Ke H. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem. J. 408 (2007) 193-201
20. Blick S.K., Dhillon S., and Keam S.J. Teriparatide: a review of its use in osteoporosis. Drugs 68 (2008) 2709-2737